The altered state is not the evidence.
Four drugs are often placed under one bright word. Their legal status, evidence and medical oversight are not remotely the same.
Evidence and regulatory status checked August 28, 2026. Licensed-prescriber and legal review are pending; no review badge is claimed.
California has no licensed psilocybin or MDMA therapy system.
Psilocybin and MDMA remain investigational and federally controlled. Ketamine can be prescribed off-label by a licensed prescriber. Esketamine has specific FDA-approved depression uses and a required supervised safety program. “Decriminalized,” “breakthrough,” and “allowed to enter a trial” do not mean “approved treatment.”¹ ² ³
Name the drug before you judge the offer.
A trial is not a clinic.
Psilocybin is not FDA-approved. In California, the lawful treatment route is a registered research study—not a paid “facilitation” service borrowing the language of research.
→02InvestigationalMDMAPromising PTSD results did not create an approved treatment.
MDMA remains federally controlled and is not FDA-approved for PTSD. Established PTSD care and registered trials remain the treatment routes.
→03Off-labelKetamineLegal prescribing, with standards you must inspect.
Ketamine is an approved anesthetic, but psychiatric use is off-label. The prescriber, route, monitoring, emergency plan and full course price are part of the decision.
→04FDA-approved usesEsketamineA specific drug, label and supervised program.
Spravato has FDA-approved adult depression indications. It is administered in a certified setting with at least two hours of monitoring—not dispensed for use at home.
→A real signal. A research-stage answer.
Randomized phase 2 studies reported reductions in depression scores after supervised psilocybin with psychological support. The trials were small compared with ordinary drug-approval programs, selected participants carefully, and do not establish a safe consumer service for everyone. One treatment-resistant-depression study did not show a sustained response through 12 weeks on its key sustained measure.⁴ ⁵
FDA’s July 2026 final guidance exists because psychedelic trials have unusual problems: masking is difficult, psychological support may affect the result, effects can last for hours, and safety monitoring matters. Guidance for research is not approval of a drug.¹
Read the evidence and safety screen →A positive trial and an approved treatment are different events.
Phase 3 trials reported improvement in PTSD symptoms with MDMA-assisted therapy. MDMA nevertheless remains unapproved and federally controlled. FDA convened an advisory committee on the application in 2024; an advisory meeting and a development program do not themselves authorize clinical use.³ ⁶
If you need PTSD care now, compare established trauma treatments. If you want research participation, verify the study in the federal registry and read its eligibility, location, sponsor and recruitment status yourself.
Make the offer survive six ordinary questions.
- What exact drug, dose and route are you offering?“Psychedelic medicine” is not a medication name.
- Is this FDA-approved, off-label prescribing, or a registered clinical trial?Those are three different legal and evidence categories.
- Who prescribes or administers it, and what California licence do they hold?Verify the licence independently; a training certificate is not a state health-care licence.
- Who screens for psychosis, mania, heart risk, medicines and substance use?A ceremonial intake is not a medical risk assessment.
- What can the setting manage if blood pressure rises, breathing changes or I become confused?Ask what happens onsite, not merely which emergency room is nearby.
- What is the complete price through follow-up?Include screening, drug sessions, monitoring, preparation, integration and maintenance.
A study record should answer more questions than an advertisement.
Use ClinicalTrials.gov. Filter to California and recruiting status. Confirm the official study contact on the registry, then ask about eligibility, randomization, placebo or comparator, travel, costs, compensation, follow-up and who pays for an injury. Never pay a third party merely to put you on a “trial waitlist.”
Search the federal trial registry →No clinic rankings. No miracle arithmetic. No legality by implication.
We do not rank providers, repeat testimonials, or call a local enforcement policy a treatment licence. Future directory results will use your filters and verified facts. Payment will never purchase a higher position.
See the evidence method →The documents behind the distinctions.
- U.S. Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, final guidance issued July 2026.
- Drug Enforcement Administration, Psilocybin Drug Fact Sheet, federal Schedule I status.
- U.S. Food and Drug Administration, selected FDA activities, including the June 2024 MDMA advisory-committee meeting; FDA, Spravato prescribing information.
- Raison et al., single-dose psilocybin for major depressive disorder, randomized phase 2 trial, JAMA, 2023.
- Goodwin et al., single-dose psilocybin for treatment-resistant depression, phase 2 trial, New England Journal of Medicine, 2022.
- Mitchell et al., MDMA-assisted therapy for moderate to severe PTSD, phase 3 trial, Nature Medicine, 2023.
- Governor of California, SB 58 veto message, October 7, 2023. The proposed statewide decriminalization measure did not become law.
Educational information, not individual medical or legal advice. Evidence and status checked August 28, 2026. Licensed-prescriber and legal review are pending.